LABU — Direxion Daily S&P Biotech Bull 3x Shares ETF
LABU seeks 3x the daily return of the S&P Biotech Select Industry Index, providing amplified exposure to biotech stocks. WARNING: Biotech is one of the most volatile equity sectors due to binary clinical trial outcomes and FDA approval decisions. Amplifying this inherent volatility with 3x leverage makes LABU exceptionally risky. A single FDA rejection can cause a 20–40% sector move in a day, and LABU amplifies this to potentially catastrophic levels. LABU is designed for short-term trading only.
Top Holdings
Strategy
- →SHORT-TERM TRADING ONLY — biotech volatility amplified 3x creates extreme single-day moves
- →Use for tactical biotech momentum plays around specific FDA catalysts or sector rotations
- →Monitor FDA decision calendars, clinical trial readouts, and biotech sector sentiment
- →Limit position size aggressively — a single adverse FDA ruling can cause catastrophic LABU losses
Best For
- ✓Short-term biotech sector traders who closely follow FDA calendars and clinical data
- ✓Sophisticated investors using LABU for time-limited amplified biotech sector momentum
- ✓Active traders who can exit quickly around binary biotech catalysts
- ✓Those who specifically want biotech sector leverage rather than broader healthcare
Key Risks
- ⚠EXTREME RISK — biotech binary events (FDA approval/rejection) combined with 3x leverage create catastrophic loss potential
- ⚠Biotech sector drawdowns of 50%+ from 3x leverage happened in 2021–2022
- ⚠Single clinical trial failure can cause massive LABU losses in a single day
- ⚠Very high expense ratio (0.96%) plus leverage costs
Similar ETFs
Frequently Asked Questions
Why is biotech so volatile?
Biotech companies' values are largely determined by drug pipeline success or failure. A single Phase 3 clinical trial failure or FDA rejection can destroy 50–80% of a company's value overnight. This binary event risk multiplied across a sector with many such events creates extreme volatility. This is educational content, not financial advice.
Is LABU appropriate around biotech earnings?
LABU can move dramatically around biotech earnings and especially around FDA decisions. For very short-term (days) trading around known catalysts, some traders use LABU, but the binary risk means losses can be catastrophic if the outcome is unfavorable. This is educational content, not financial advice.
How did LABU perform in 2021–2022?
LABU fell approximately 90%+ from its 2021 peak to its 2022 lows as the biotech sector experienced a prolonged bear market driven by rising rates, clinical failures, and risk-off sentiment. This is educational content, not financial advice.
What is the difference between LABU and IBB?
IBB is an unlevered biotech ETF tracking a different index. LABU provides 3x daily leverage on the S&P Biotech Select Industry Index. IBB is suitable for long-term investors; LABU is for short-term traders only. This is educational content, not financial advice.
Does LABU track large or small biotech companies?
LABU tracks the S&P Biotech Select Industry Index, which is equal-weighted and includes a broad range of biotech companies, with significant small and mid-cap exposure. This makes LABU more volatile than large-cap biotech ETFs like IBB. This is educational content, not financial advice.
Recommended Resources
Tools & books I actually use and recommend
Interactive Brokers
Low commissions, global market access, and professional-grade tools. This is where I hold my positions.
Open an AccountA Random Walk Down Wall Street
Burton Malkiel's classic case for index investing. The book that convinced millions to stop stock-picking.
View on AmazonTradingView
Best charting platform out there. Real-time data, screeners, and a community of millions of traders.
Try TradingViewSome links above are affiliate links. I only recommend products I personally use. See my full disclosures.